{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:12:35Z","timestamp":1793293955230,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T00:00:00Z","timestamp":1688860800000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.autrev.2022.103137","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T13:45:09Z","timestamp":1657115109000},"page":"103137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["TAFRO syndrome: A severe manifestation of Sjogren's syndrome? A systematic review"],"prefix":"10.1016","volume":"21","author":[{"given":"Lucile","family":"Grange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Chalayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boutboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Galicier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Gramont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Killian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2022.103137_bb0005","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","article-title":"Epidemiology of primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis","volume":"74","author":"Qin","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103137_bb0010","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103137_bb0015","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.autrev.2018.05.005","article-title":"Clinical and immunological parameters of Sj\u00f6gren\u2019s syndrome","volume":"17","author":"Psianou","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1568-9972(03)00006-5","article-title":"The epidemiology of autoimmune diseases","volume":"2","author":"Cooper","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic involvement in primary Sjogren\u2019s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103137_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102762","article-title":"Sj\u00f6gren\u2019s syndrome: an undiagnosed etiology for facial pain case series with review of neurological manifestation of Sj\u00f6gren syndrome","volume":"20","author":"Borensztejn","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102447","article-title":"Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sj\u04e7gren\u2019s syndrome: a systematic review from the Italian Society of Rheumatology","volume":"19","author":"Sambataro","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nrneph.2015.174","article-title":"Renal involvement in primary Sj\u00f6gren syndrome","volume":"12","author":"Fran\u00e7ois","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.autrev.2022.103137_bb0045","doi-asserted-by":"crossref","first-page":"102987","DOI":"10.1016\/j.autrev.2021.102987","article-title":"Cancer incidence in primary Sj\u00f6gren\u2019s syndrome: Data from the French hospitalization database","volume":"20","author":"Goulabchand","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0050","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.autrev.2016.03.004","article-title":"Primary Sj\u04e7gren\u2019s syndrome: clinical phenotypes, outcome and the development of biomarkers","volume":"15","author":"Goules","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.13192","article-title":"Sj\u00f6gren syndrome-associated lymphomas: an update on pathogenesis and management","volume":"168","author":"Nocturne","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2022.103137_bb0060","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","article-title":"Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version","volume":"103","author":"Masaki","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.autrev.2022.103137_bb0065","first-page":"320","article-title":"Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly","volume":"51","author":"Takai","year":"2010","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.autrev.2022.103137_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2017.00149","article-title":"TAFRO syndrome in Caucasians: a case report and review of the literature","volume":"4","author":"Louis","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.autrev.2022.103137_bb0075","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103137_bb0080","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103137_bb0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3960\/jslrt.53.57","volume":"53","author":"Kawabata","year":"2013","journal-title":"J Clin Exp Hematop JCEH"},{"key":"10.1016\/j.autrev.2022.103137_bb0090","doi-asserted-by":"crossref","first-page":"719","DOI":"10.7326\/L20-1051","article-title":"JAK1\/2 inhibition in severe TAFRO syndrome: a case report","volume":"174","author":"Killian","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2022.103137_bb0095","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","article-title":"2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome","volume":"111","author":"Masaki","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.autrev.2022.103137_bb0100","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.25554","article-title":"Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?","volume":"94","author":"Fujimoto","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2022.103137_bb0105","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2022.103137_bb0110","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.autrev.2014.05.002","article-title":"Lupus mimickers","volume":"13","author":"Calixto","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0115","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","article-title":"Primary Sj\u00f6gren syndrome in Spain: clinical and immunologic expression in 1010 patients","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2022.103137_bb0120","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2177\/jsci.39.478","article-title":"TAFRO syndrome with primary Sjogren\u2019s syndrome","volume":"39","author":"Iwanaga","year":"2016","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"10.1016\/j.autrev.2022.103137_bb0125","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009220","article-title":"Sj\u00f6gren\u2019s syndrome manifesting as clinicopathological features of TAFRO syndrome","volume":"96","author":"Fujimoto","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2022.103137_bb0130","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/14397595.2016.1206243","article-title":"A case of TAFRO syndrome, a variant of multicentric Castleman\u2019s disease, successfully treated with corticosteroid and cyclosporine a","volume":"29","author":"Takasawa","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2022.103137_bb0135","first-page":"102","article-title":"First European case of TAFRO syndrome associated with Sjogren disease","volume":"2","author":"Abdo","year":"2014","journal-title":"Am J Intern Med"},{"key":"10.1016\/j.autrev.2022.103137_bb0140","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/0961203310381510","article-title":"Multicentric Castleman\u2019s disease representing effusion at initial clinical presentation: clinicopathological study of seven cases","volume":"20","author":"Kojima","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103137_bb0145","first-page":"8872774","article-title":"Primary Sj\u00f6gren\u2019s syndrome accompanied by clinical features of TAFRO syndrome","volume":"2020","author":"Suzuki","year":"2020","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.autrev.2022.103137_bb0150","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/ccr3.2502","article-title":"Multicentric Castleman disease with TAFRO syndrome and Sj\u00f6gren\u2019s","volume":"7","author":"Li","year":"2019","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.autrev.2022.103137_bb0155","article-title":"A case of repeated TAFRO syndrome-like symptoms and retroperitoneal hemorrhage in a patient with Sj\u00f6gren syndrome","volume":"12","author":"Ohta","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2022.103137_bb0160","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/24725625.2017.1282037","article-title":"Anasarca as the initial symptom in a Japanese girl with Sj\u00f6gren\u2019s syndrome","volume":"1","author":"Ueki","year":"2017","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.autrev.2022.103137_bb0165","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0961203317725589","article-title":"Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome","volume":"27","author":"Hasegawa","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103137_bb0170","first-page":"688","article-title":"Systemic lupus erythematosus with marked eosinophilia and clinical features mimicking TAFRO syndrome","volume":"59","author":"Tokunaga","year":"2018","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.autrev.2022.103137_bb0175","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022793","article-title":"Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor","volume":"99","author":"Kadoba","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2022.103137_bb0180","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3960\/jslrt.19021","article-title":"Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan","volume":"59","author":"Masaki","year":"2019","journal-title":"J Clin Exp Hematop JCEH"},{"key":"10.1016\/j.autrev.2022.103137_bb0185","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s10067-020-05487-5","article-title":"Sj\u00f6gren syndrome associated with protein-losing enteropathy: case-based review","volume":"40","author":"de Carvalho","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103137_bb0190","first-page":"15322","article-title":"Primary Sj\u00f6gren\u2019s syndrome accompanied by pleural effusion: a case report and literature review","volume":"8","author":"Ma","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.autrev.2022.103137_bb0195","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2177\/jsci.23.124","article-title":"Hematological abnormalities of primary Sjogren\u2019s syndrome","volume":"23","author":"Aoki","year":"2000","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"10.1016\/j.autrev.2022.103137_bb0200","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fmed.2020.00138","article-title":"Clinical characteristics of secondary immune thrombocytopenia associated with primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Dai","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.autrev.2022.103137_bb0205","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/rheumatology\/kev200","article-title":"Characterization of systemic disease in primary Sj\u00f6gren\u2019s syndrome: EULAR-SS task force recommendations for articular, cutaneous, pulmonary and renal involvements","volume":"54","author":"Ramos-Casals","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103137_bb0210","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3324\/haematol.2020.249896","article-title":"Clinical spectrum and therapeutic management of auto-immune myelofibrosis: a nation-wide study of 30 cases","volume":"106","author":"Mertz","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2022.103137_bb0215","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2022.103137_bb0220","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cyto.2012.12.021","article-title":"Emerging avenues linking inflammation, angiogenesis and Sj\u00f6gren\u2019s syndrome","volume":"61","author":"Lisi","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2022.103137_bb0225","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3389\/fimmu.2019.00817","article-title":"Subclinical atherosclerosis in primary Sj\u00f6gren\u2019s syndrome: does inflammation matter?","volume":"10","author":"Bartoloni","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103137_bb0230","first-page":"27","article-title":"Primarily VEGF-driven etiopathogenesis of Tafro syndrome and fibroblastic reticular cells as a probable castleman cell - qualitative metasynthesis","volume":"136","author":"Lee","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103137_bb0235","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/gene.2012.9","article-title":"Sj\u00f6gren\u2019s syndrome pathological neovascularization is regulated by VEGF-A-stimulated TACE-dependent crosstalk between VEGFR2 and NF-\u03baB","volume":"13","author":"Sisto","year":"2012","journal-title":"Genes Immun"},{"key":"10.1016\/j.autrev.2022.103137_bb0240","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0961203318801673","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"27","author":"Bowman","year":"2018","journal-title":"Lupus"},{"issue":"Suppl. 112","key":"10.1016\/j.autrev.2022.103137_bb0245","first-page":"102","article-title":"How immunological profile drives clinical phenotype of primary Sj\u00f6gren\u2019s syndrome at diagnosis: analysis of 10,500 patients (Sj\u00f6gren big data project)","volume":"36","author":"Brito-Zer\u00f3n","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103137_bb0250","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.autrev.2015.07.002","article-title":"Anti-SSA\/SSB-negative Sj\u00f6gren\u2019s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution","volume":"14","author":"Quartuccio","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0255","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman\u2019s disease: a systematic literature review","volume":"3","author":"Liu","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.autrev.2022.103137_bb0260","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type I interferons in Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren\u2019s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren\u2019s related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103137_bb0270","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-021-23472-7","article-title":"A new molecular classification to drive precision treatment strategies in primary Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Soret","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2022.103137_bb0275","doi-asserted-by":"crossref","first-page":"17609","DOI":"10.1073\/pnas.1209724109","article-title":"Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases","volume":"109","author":"Hall","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2022.103137_bb0280","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135031","article-title":"Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease","volume":"5","author":"Pai","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2022.103137_bb0285","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0290","doi-asserted-by":"crossref","first-page":"42316","DOI":"10.1038\/srep42316","article-title":"Elevated serum interferon \u03b3-induced protein 10 kDa is associated with TAFRO syndrome","volume":"7","author":"Iwaki","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2022.103137_bb0295","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1038\/s41598-019-43714-5","article-title":"Elevated cytokine levels in tears and saliva of patients with primary Sj\u00f6gren\u2019s syndrome correlate with clinical ocular and oral manifestations","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"issue":"168","key":"10.1016\/j.autrev.2022.103137_bb0300","first-page":"3195","article-title":"IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking","volume":"2002","author":"Dufour","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.autrev.2022.103137_bb0305","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.autrev.2010.05.006","article-title":"B-cell tolerance breakdown in Sj\u00f6gren\u2019s syndrome: focus on BAFF","volume":"9","author":"Varin","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0315","article-title":"Akt and mTOR in B cell activation and differentiation","volume":"3","author":"Fruman","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103137_bb0320","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000701","article-title":"Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sj\u00f6gren\u2019s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?","volume":"5","author":"Blokland","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2022.103137_bb0325","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jconrel.2013.07.016","article-title":"A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sj\u00f6gren\u2019s syndrome","volume":"171","author":"Shah","year":"2013","journal-title":"J Control Release Off J Control Release Soc"},{"key":"10.1016\/j.autrev.2022.103137_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102984","article-title":"Therapeutic mTOR blockade in systemic autoimmunity: implications for antiviral immunity and extension of lifespan","volume":"20","author":"Geier","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0335","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1172\/JCI126091","article-title":"Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease","volume":"130","author":"Fajgenbaum","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2022.103137_bb0340","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1182\/blood.2019002792","article-title":"Increased mTOR activation in idiopathic multicentric Castleman disease","volume":"135","author":"Arenas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103137_bb0345","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrrheum.2010.118","article-title":"Pathogenetic mechanisms in the initiation and perpetuation of Sj\u00f6gren\u2019s syndrome","volume":"6","author":"Voulgarelis","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2022.103137_bb0350","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.autrev.2018.12.008","article-title":"The pipeline of targeted therapies under clinical development for primary Sj\u00f6gren\u2019s syndrome: a systematic review of trials","volume":"18","author":"Felten","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103137_bb0355","article-title":"The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome","volume":"215","author":"Kurose","year":"2019","journal-title":"Pathol Res Pract"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:27:44Z","timestamp":1761600464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222001070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1568997222001070"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103137","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAFRO syndrome: A severe manifestation of Sjogren's syndrome? A systematic review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103137"}}